Sensible Use of Tumor Markers;Sinnvoller Einsatz von Tumormarkern

LaboratoriumsMedizin

Volumn 25, Issue 9-10, 2001, Pages 327-336

  Stieber, Petra ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Abgeschnittene Werte; Abh ngigkeit von der Methode; cut off values; dependency on method; Deutung; in vivo and in vitro influences; In vivo und in vitro Einfl ssen; individual baseline value; Individueller Ausgangswert; interpretation; tumor markers; Tumormarker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; MEDICAL DECISION MAKING; PATIENT MONITORING; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 0035184067     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labm.2001.25.9-10.327     Document Type: Article

References (14)

1. Anonymous. Arbeitsgruppe Qualiätskontrolle und Standard-Isicrung von Tumormarkertests im Rahmen der Hamburger Symposien über Tumormarker. Tumordiagn u Ther 1993;13:XIX–XXII.
2. Anonymous. Working Group on Tumor Marker Criteria (WGTMC). Tumor Biol 1990;11:287–288.
3. Anonymous: Quality control and standardization of tumour marker tests. Tumor Biol 1993;14:131–135.
4. Hayes, DF., Bast, RC., Desch, CE., Fritsche, H., Kemeny, ND., Jessup, JM., Locker, GY., Macdonald, JS., Mennel, RG., Norton, L., Ravdin, P., Taube, S., Winn, RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Nat Cancer Inst 1996;88:1456-66.
5. Fateh-Moghadam, A., Stieber, P. Sensible use of tumour markers. Jürgen Hartmann Verlag GmbH: Marloffstein-Rathsberg, Germany, 1993.
6. Stieber, P., Poley, S., Fateh-Moghadam, A. Tumormarker-gibt es Befunde ohne Krankheitswert? Der Bay Int 1996;16(3):22–31.
7. Lin, CL., Changchien, CS., Chen, YS. Mirizzi's syndrome with a high CA19-9 level mimicking cholangiocarcinoma. Am J Gastroenterol 1997;12:2309–2310.
8. Mann, DV., Edwards, R., Ho, S., Lau, WY., Glazer, G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000:5:474–479.
9. Fiebig, M., Stieber, P., Knitza, R., Hofmann, K., Nagel, D., Fateh-Moghadam, A. Tumorassoziierte Antigene in der Schwangerschaft, Der Bayint 1994;14:52–56
10. Hasholzner, U., Stieber, P., Baumgartner, L., Pahl, H., Meier, W., Fateh-Moghadam, A. Methodical and clinical evaluation of three automized CA 125 Assays compared with the CA 125 II RIA (Centocor). Tumordiagn u Ther 1994;15:114–117.
11. Schambeck C., Schmeller, N., Stieber, P., Jansen, HM., Pahl, H., Schneider, W., Fateh-Moghadam, A, A methodological and clinical comparison of the ACS PSA-Assay (Ciba Corning) and the Tan-dem-E PSA-Assay (Hybritech) in prostate cancer. Urology 1995; 46(2): 195–199.
12. Thomas, L., Stieber, P. Malignant diseases. In: Thomas L (ed) Clinical Laboratory Diagnostics. TH-Books Verlag, Frankfurt, 1998:936–941.
13. Semjonow, A., Weining, C., Oberpenning, F., Heinecke, A., Terpe, A., Schmid, HP. Application of assay-specific cut-off values: results of the assay comparison study for PSA. Eur Urol 1999;35(Suppl 2): 18.
14. Semjonow, A., Oberpenning, F., Weining, C. Schön, M. Schmid, HP., Brandt, B., De Angelis, G., Heinecke, A., Hamm, M., Stieber, P., Hertle, L. Do modifications of non-equimolar assays for total prostate specific antigen improve clinical performance? Clin Chem 2001;47:1472–1475.